OR WAIT 15 SECS
Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.
With so many blockbuster drugs falling off the patent cliff, research-based drug companies are now embracing new development paradigms to increase R&D productivity.
With so many blockbuster drugs falling off the patent cliff, research-based drug companies are now embracing new development paradigms to increase R&D productivity. However, drug developers need to fully identify and address root causes of R&D inefficiency if they want to replenish their sparse R&D pipelines, according to the Tufts Center for the Study of Drug Development (CSDD).
“Many companies are taking steps to improve clinical success rates and reduce the cost of new product development, including utilizing enhanced clinical trial designs, making greater use of biomarkers and adopting sophisticated statistical analyses,” said Kenneth I Kaitin, director of Tufts CSDD in a press release. “It’s a good start but in a world shaped by increased patent expirations, diminished cash flow, and fewer promising breakthrough products, companies will need to hone their efforts to streamline development.”
Kaitin’s comments were made in connection with the release of Tufts CSDD outlook 2013 report on pharmaceutical and biopharmaceutical trends which highlighted the following near-term trends:
Kaitin is, however, optimistic about the future of bioinnovation and said, “The emergence of open innovation models, where scientists worldwide openly share knowledge, and novel partnerships and alliances hold significant promise to transform the nature, pace, and cost of new drug development—to the benefit of patients, as well as to drug sponsors, their development partners, and investors.”